SCHEMBL4510504

SCHEMBL4510504

Cc1ccc(C2=NC(C)(C)CN2C(c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)c(F)c1F

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 6/20 0.47
CYP3A4 P08684 2/20 0.42
MAP1LC3B Q9GZQ8 2/20 0.42
CYP2C19 P33261 1/20 0.42
KCNH2 Q12809 1/20 0.42
TDP1 Q9NUW8 1/20 0.37
CASR P41180 1/20 0.37
EGFR P00533 1/20 0.35
ALDH1A1 P00352 2/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.34
LMNA P02545 1/20 0.34
PDE6D O43924 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4522994 0.90 KIF11 (0.45) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL13865432 0.88 KIF11 (0.52) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL4520829 0.88 KIF11 (0.52) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL4516234 0.87 KIF11 (0.49) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL13865433 0.87 KIF11 (0.49) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL4520991 0.86 KIF11 (0.45) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL4523770 0.86 KIF11 (0.44) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL4528790 0.86 KIF11 (0.45) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL4514039 0.85 KIF11 (0.50) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL4518681 0.84 KIF11 (0.44) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528137-B2 Compounds, compositions, and methods CYTOKINETICS, INC. (US) 2009-05-05 US disclosed
US-7214800-B2 Compounds, compositions, and methods CYTOKINETICS, INC. (US) 2007-05-08 US disclosed
EP-1553931-A4 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS INC (US) 2006-08-30 EP disclosed
US-20060094735-A1 Compounds, compositions, and methods CYTOKINETICS, INC. 2006-05-04 US disclosed
EP-1553931-A1 COMPOUNDS, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2005-07-20 EP disclosed
US-20040077668-A1 Compounds, compositins, and methods CYTOKINETICS, INC. 2004-04-22 US disclosed
WO-2003097053-A1 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077668-A1 Compounds, compositins, and methods CEP170, PSAP, PACSIN2 KIF11 1233/4885CYP3A4 4624/4885MAP1LC3B 1225/4885
US-20060094735-A1 Compounds, compositions, and methods ALPP, PCNA, MKI67 KIF11 562/4885CYP3A4 4722/4885MAP1LC3B 1330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.